http://www.craneware.com/

Craneware, Inc. is a leading supplier of business intelligence and revenue cycle software that provides clients with chargemaster management software and products designed to optimize legitimate reimbursements and assist in managing the revenue cycle through better information, workflow, pricing strategy, capture of lost revenue and best practice modeling. Our innovative and scalable products are designed to ensure that you have the information you need to succeed in healthcare financial management.

A talented mix of employees from the healthcare industry, software engineering, business consulting, customer support and training provide the perfect blend for providing extremely powerful solutions to problems faced by hospital's financial teams.

Our consultant's years of experience in the healthcare industry are the vital source of financial, clinical and coding expertise that together with talented software developers combine to make our products so effective.

Our dedicated support team work hard at ensuring our customers always come first and pride themselves on exemplary service throughout the relationship from first install to advanced user training. Installation times are in weeks instead of months, Support responses are in minutes instead of days.

Headquartered in Scotland with offices across the US, Craneware delivers unparalleled solutions to the problems facing healthcare financial managers every day.

Final Results
RNS
RNS Number : 6425Z
Craneware plc
04 September 2018

Craneware plc
("Craneware", "the Group" or the "Company")

Final Results

4 September 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its audited results for the year ended 30 June 2018.

Financial Highlights (US dollars)
· Revenue increased 16% to $67.1m (FY17: $57.8m)
· Adjusted EBITDA1. increased 20% to $21.6m (FY17: $18.0m)
· Profit before tax increased 12% to $18.9m (FY17: $16.9m)
· Basic adjusted EPS2. increased 17% to $0.602 (FY17: $0.514) and adjusted diluted EPS increased to $0.591 (FY17: $0.503)
· Total visible revenue increased 20% to $192.9m (FY17 same 3 year period: $160.7m)
· Continued operating cash conversion above 100% of Adjusted EBITDA
· Renewal rate remains above 100% by dollar value
· Cash at year-end of $52.8m (FY17: $53.2m) after having returned $23.2m to shareholders via a share buyback and dividends, while also investing $4.2m in the Employee Benefit Trust
· Proposed final dividend of 14.0p (18.48 cents) (FY17: 11.3p, 14.71 cents) per share giving a total dividend for the year of 24.0p (36.68 cents) (FY17: 20.0p, 26.04 cents) per share

1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation and share based payments.
2. Adjusted Earnings per share calculations allow for the tax adjusted acquisition costs and share related transactions together with amortisation on acquired intangible assets.

Operational Highlights

· Over 100% increase in new sales in the year, including five significant contracts wins or contract extensions
· Continued supportive market environment as the US healthcare market evolves towards value-based care, with a critical dependency on accurate financial and operating data
· Continued high levels of customer acquisition and retention
· Increasing market engagement with newly launched cloud-based platform, Trisus™
· Strong sales and opportunities across the product suite and across all classes of hospital providers, including for the first Trisus product: Trisus Claims Informatics
· Early adopters reporting positive results for our new Craneware Healthcare Intelligence software, the next Trisus software release

Outlook

· Record sales pipeline for the current financial year
· Board confident in outlook for the year and beyond

Keith Neilson, CEO of Craneware plc commented, "While the past year has been outstanding in terms of financial results and operational progress, this is by no means the end of the journey and we are excited by the far greater opportunity that lies ahead. It is clear that the investments we have made into the organisation's design, people and products are delivering excellent results, and we will continue to invest in our people and business to ensure we have the capabilities to succeed. We believe that the breadth of our customer base and the quantity of data within our solutions means we have the opportunity to sit at the heart of the move to value-based economics; collating and analysing the information that will support hospital-wide decision making and ultimately have a positive impact on the quality of healthcare.

"With an ongoing, growing market opportunity, a record sales pipeline and increasing long-term revenue visibility, we enter the new financial year with great confidence for the future and the ongoing success of the business."

Broker Forecast - Peel Hunt issues a broker note on Craneware PLC
Peel Hunt today reaffirms its buy investment rating on Craneware PLC (LON:CRW) and raised its price target to 2800p (from 2500p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Grant of options and long term incentive plan awards

Director Deals - Craneware PLC (CRW)
BFN
Keith Neilson, Chief Executive Officer, bought 4,848 shares in the company on the 7th September 2018 at a price of 3081.91p. The Director now holds 3,382,647 shares.

Story provided by StockMarketWire.com
Director deals data provided by www.sharesmagazine.co.uk

500p above latest broker price and new high.

Going into orbit.

AGM Statement and Capital Markets Day
RNS
RNS Number : 3859G
Craneware plc
06 November 2018

Craneware plc
("Craneware", "the Group" or the "Company")
AGM Statement and Capital Markets Day

6 November 2018 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 1pm. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:

"We have experienced a positive start to trading in the first four months of the year, in line with management expectations. Strong demand has continued across our enlarged product suite, from both new and existing customers.

"Our recent Financial Performance Summit in the US was the most well attended in the history of the Company, with representatives from approximately 600 hospitals. From the workshops and panel discussions at the event, it is evident that the move to value-based care is growing in momentum and hospitals are preparing for this shift. As we launch our new Trisus products over the coming weeks and continue to invest in future products over the coming years, we see the opportunity for Craneware to become a major player in the healthcare market, ensuring hospitals have the tools to thrive in this near era, improving both margins and patient outcomes.

"With a continued high level of recurring revenues, a growing customer base, healthy cash balances and significantly increased addressable market through our expanding product suite, we look to the future with confidence."

Capital Markets Day

Craneware is holding a Capital Markets Day for institutional investors and analysts this morning at 9am in the offices of Peel Hunt in London. The presentations will discuss the evolution of the US healthcare market and provide further insight into Craneware's newly launched Trisus products, including Trisus Healthcare Intelligence. Keith Neilson, CEO, and Craig Preston, CFO, will be joined by other members of the Craneware Board and senior leadership team. No further update on trading will be provided.

10:30 15/11/2018
Broker Forecast - Berenberg issues a broker note on Craneware PLC
Berenberg today initiates coverage of Craneware PLC (LON:CRW) with a buy investment rating and price target of 3600p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

i really cannot get excited about this stock though many do ....... it's totally illiquid and MM-only with a spread that is usually 100/200p